{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:31:11Z","timestamp":1788957071581,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In 2018, a grant was provided for an evidence-based guideline on osteoporosis and fracture prevention based on 10 clinically relevant questions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary working group was formed with delegates from Dutch scientific and professional societies, including representatives from the patient\u2019s organization and the Dutch Institute for Medical Knowledge. The purpose was to obtain a broad consensus among all participating societies to facilitate the implementation of the updated guideline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Novel recommendations in our guideline are as follows:<\/jats:p>\n                    <jats:p>- In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA.<\/jats:p>\n                    <jats:p>- Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk;<\/jats:p>\n                    <jats:p>- Directly starting with zoledronic acid in patients 75\u00a0years and over with a hip fracture (independent of DXA);<\/jats:p>\n                    <jats:p>- Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk;<\/jats:p>\n                    <jats:p>- A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 \u201crelatively new statements\u201d that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-024-01378-3","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T07:02:17Z","timestamp":1712041337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena"],"prefix":"10.1007","volume":"19","author":[{"given":"J. P.","family":"van den Bergh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Geusens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J. G.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J. M.","family":"Elders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"de Klerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Oostwaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. C.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. F.","family":"Lems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"1378_CR1","doi-asserted-by":"publisher","unstructured":"Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M et al (2016) GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ 353:i2016 https:\/\/doi.org\/10.1136\/bmj.i2016","DOI":"10.1136\/bmj.i2016"},{"key":"1378_CR2","doi-asserted-by":"publisher","unstructured":"Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al (2016) GRADE Evidence to Decision (EtD) frameworks a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 353:i2089 https:\/\/doi.org\/10.1136\/bmj.i2089","DOI":"10.1136\/bmj.i2089"},{"issue":"1","key":"1378_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/ard.2006.058313","volume":"66","author":"WF Lems","year":"2007","unstructured":"Lems WF (2007) Clinical relevance of vertebral fractures. Ann Rheum Dis 66(1):2\u20134. https:\/\/doi.org\/10.1136\/ard.2006.058313","journal-title":"Ann Rheum Dis"},{"key":"1378_CR4","doi-asserted-by":"publisher","unstructured":"Kendler DL, Bauer DC, Davison KS, Dian L, Hanley DA, Harris ST et al (2016) Vertebral fractures clinical importance and management. Am J Med 129(2)221.e1\u201310 https:\/\/doi.org\/10.1016\/j.amjmed.2015.09.020","DOI":"10.1016\/j.amjmed.2015.09.020"},{"issue":"3","key":"1378_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/jbmr.3669","volume":"34","author":"B Lentle","year":"2019","unstructured":"Lentle B, Koromani F, Brown JP, Oei L, Ward L, Goltzman D et al (2019) The radiology of osteoporotic vertebral fractures revisited. J Bone Miner Res 34(3):409\u2013418. https:\/\/doi.org\/10.1002\/jbmr.3669","journal-title":"J Bone Miner Res"},{"issue":"9548","key":"1378_CR6","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/S0140-6736(06)69691-8","volume":"368","author":"A Cooper","year":"2006","unstructured":"Cooper A (2006) Compliance with treatment for osteoporosis. Lancet 368(9548):1648. https:\/\/doi.org\/10.1016\/S0140-6736(06)69691-8","journal-title":"Lancet"},{"issue":"2","key":"1378_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/jbmr.5650070214","volume":"7","author":"C Cooper","year":"1992","unstructured":"Cooper C, Atkinson EJ, O\u2019Fallon WM, Melton LJ 3rd (1992) Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985\u20131989. J Bone Miner Res 7(2):221\u2013227. https:\/\/doi.org\/10.1002\/jbmr.5650070214","journal-title":"J Bone Miner Res"},{"issue":"7","key":"1378_CR8","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1359\/JBMR.050314","volume":"20","author":"HA Fink","year":"2005","unstructured":"Fink HA, Milavetz DL, Palermo L, Nevitt MC, Cauley JA, Genant HK et al (2005) What proportion of incident radiographic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 20(7):1216\u20131222. https:\/\/doi.org\/10.1359\/JBMR.050314","journal-title":"J Bone Miner Res"},{"issue":"3","key":"1378_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00198-020-05804-3","volume":"32","author":"WF Lems","year":"2021","unstructured":"Lems WF, Paccou J, Zhang J, Fuggle NR, Chandran M, Harvey NC et al (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporos Int 32(3):399\u2013411. https:\/\/doi.org\/10.1007\/s00198-020-05804-3","journal-title":"Osteoporos Int"},{"issue":"4","key":"1378_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721\u2013739. https:\/\/doi.org\/10.1359\/jbmr.2000.15.4.721","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1378_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00198-006-0306-8","volume":"18","author":"ES Siris","year":"2007","unstructured":"Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH (2007) Enhanced prediction of fracture risk combining vertebral fracture status and BMD. Osteoporos Int 18(6):761\u2013770. https:\/\/doi.org\/10.1007\/s00198-006-0306-8","journal-title":"Osteoporos Int"},{"issue":"9","key":"1378_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"issue":"15","key":"1378_CR13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"10117","key":"1378_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V et al (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"},{"issue":"1","key":"1378_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","volume":"31","author":"JA Kanis","year":"2020","unstructured":"Kanis JA, Harvey NC, McCloskey E, Bruyere O, Veronese N, Lorentzon M et al (2020) Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 31(1):1\u201312. https:\/\/doi.org\/10.1007\/s00198-019-05176-3","journal-title":"Osteoporos Int"},{"key":"1378_CR16","doi-asserted-by":"publisher","unstructured":"Griffin XL, Parsons N, Achten J, Fernandez M, Costa ML (2015) Recovery of health-related quality of life in a United Kingdom hip fracture population The Warwick Hip Trauma Evaluation a prospective cohort study. Bone Joint J 97-B(3):372\u201382 https:\/\/doi.org\/10.1302\/0301-620X.97B3.35738","DOI":"10.1302\/0301-620X.97B3.35738"},{"issue":"8","key":"1378_CR17","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S2666-7568(23)00086-7","volume":"4","author":"P Baji","year":"2023","unstructured":"Baji P, Patel R, Judge A, Johansen A, Griffin J, Chesser T et al (2023) Organisational factors associated with hospital costs and patient mortality in the 365 days following hip fracture in England and Wales (REDUCE): a record-linkage cohort study. Lancet Healthy Longev 4(8):e386\u2013e398. https:\/\/doi.org\/10.1016\/S2666-7568(23)00086-7","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"1378_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11657-023-01282-2","volume":"18","author":"Z Mohsin","year":"2023","unstructured":"Mohsin Z, Javaid MK, Johansen A (2023) Current approaches to secondary prevention after hip fracture in England and Wales - an analysis of trends between 2016 and 2020 using the National Hip Fracture Database (NHFD). Arch Osteoporos 18(1):93. https:\/\/doi.org\/10.1007\/s11657-023-01282-2","journal-title":"Arch Osteoporos"},{"issue":"18","key":"1378_CR19","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18):1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa074941","journal-title":"N Engl J Med"},{"issue":"10","key":"1378_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s40265-019-01145-6","volume":"79","author":"HG Raterman","year":"2019","unstructured":"Raterman HG, Bultink IEM, Lems WF (2019) Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs 79(10):1065\u20131087. https:\/\/doi.org\/10.1007\/s40265-019-01145-6","journal-title":"Drugs"},{"issue":"1","key":"1378_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00198-014-2883-2","volume":"26","author":"S Silverman","year":"2015","unstructured":"Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int 26(1):419\u2013420. https:\/\/doi.org\/10.1007\/s00198-014-2883-2","journal-title":"Osteoporos Int"},{"key":"1378_CR22","unstructured":"Zorginstituut Nederland. Verbetersignalement osteoporose. https:\/\/www.zorginstituutnederland.nl\/werkagenda\/publicaties\/rapport\/2020\/08\/11\/zinnige-zorgverbetersignalement-osteoporose"},{"issue":"11","key":"1378_CR23","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1002\/art.24879","volume":"60","author":"KG Saag","year":"2009","unstructured":"Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K et al (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 60(11):3346\u20133355. https:\/\/doi.org\/10.1002\/art.24879","journal-title":"Arthritis Rheum"},{"issue":"9671","key":"1378_CR24","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","volume":"373","author":"DM Reid","year":"2009","unstructured":"Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373(9671):1253\u20131263. https:\/\/doi.org\/10.1016\/S0140-6736(09)60250-6","journal-title":"Lancet"},{"issue":"6","key":"1378_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2213-8587(18)30075-5","volume":"6","author":"KG Saag","year":"2018","unstructured":"Saag KG, Wagman RB, Geusens P, Adachi JD, Messina OD, Emkey R et al (2018) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol 6(6):445\u2013454. https:\/\/doi.org\/10.1016\/S2213-8587(18)30075-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1378_CR26","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s00198-010-1372-5","volume":"22","author":"JC Netelenbos","year":"2011","unstructured":"Netelenbos JC, Geusens PP, Ypma G, Buijs SJ (2011) Adherence and profile of non-persistence in patients treated for osteoporosis\u2013a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 22(5):1537\u20131546. https:\/\/doi.org\/10.1007\/s00198-010-1372-5","journal-title":"Osteoporos Int"},{"issue":"11","key":"1378_CR27","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00198-020-05507-9","volume":"31","author":"G Koller","year":"2020","unstructured":"Koller G, Goetz V, Vandermeer B, Homik J, McAlister FA, Kendler D, Ye C (2020) Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporos Int 31(11):2093\u20132102. https:\/\/doi.org\/10.1007\/s00198-020-05507-9","journal-title":"Osteoporos Int"},{"issue":"5","key":"1378_CR28","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab 104(5):1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2019-00192","journal-title":"J Clin Endocrinol Metab"},{"key":"1378_CR29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3389\/fphar.2019.00882","volume":"10","author":"LF Zeng","year":"2019","unstructured":"Zeng LF, Pan BQ, Liang GH, Luo MH, Cao Y, Guo D et al (2019) Does routine anti-osteoporosis medication lower the risk of fractures in male subjects? An updated systematic review with meta-analysis of clinical trials. Front Pharmacol 10:882. https:\/\/doi.org\/10.3389\/fphar.2019.00882","journal-title":"Front Pharmacol"},{"issue":"1","key":"1378_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40520-018-1109-4","volume":"31","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Scientific Advisory Board of the European Society for C, Economic Aspects of O et al (2019) Executive summary of European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Aging Clin Exp Res 31(1):15\u20137. https:\/\/doi.org\/10.1007\/s40520-018-1109-4","journal-title":"Aging Clin Exp Res"},{"issue":"24","key":"1378_CR31","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927\u20132938. https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"JAMA"},{"issue":"7","key":"1378_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","volume":"174","author":"DC Bauer","year":"2014","unstructured":"Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A et al (2014) Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med 174(7):1126\u20131134. https:\/\/doi.org\/10.1001\/jamainternmed.2014.1232","journal-title":"JAMA Intern Med"},{"issue":"12","key":"1378_CR33","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR et al (2014) Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab 99(12):4546\u20134554. https:\/\/doi.org\/10.1210\/jc.2014-1971","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1378_CR34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/annrheumdis-2016-210289","volume":"76","author":"WF Lems","year":"2017","unstructured":"Lems WF, Dreinhofer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J et al (2017) EULAR\/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures. Ann Rheum Dis 76(5):802\u2013810. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210289","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1378_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00198-020-05377-1","volume":"31","author":"MK Javaid","year":"2020","unstructured":"Javaid MK, Sami A, Lems W, Mitchell P, Thomas T, Singer A et al (2020) A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. Osteoporos Int 31(7):1193\u20131204. https:\/\/doi.org\/10.1007\/s00198-020-05377-1","journal-title":"Osteoporos Int"},{"issue":"10","key":"1378_CR36","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1002\/jbmr.1698","volume":"27","author":"JA Eisman","year":"2012","unstructured":"Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A et al (2012) Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 27(10):2039\u20132046. https:\/\/doi.org\/10.1002\/jbmr.1698","journal-title":"J Bone Miner Res"},{"issue":"1","key":"1378_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bone.2003.10.001","volume":"34","author":"SC Schuit","year":"2004","unstructured":"Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34(1):195\u2013202. https:\/\/doi.org\/10.1016\/j.bone.2003.10.001","journal-title":"Bone"},{"issue":"5","key":"1378_CR38","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1210\/jc.2010-2135","volume":"96","author":"SP Bours","year":"2011","unstructured":"Bours SP, van Geel TA, Geusens PP, Janssen MJ, Janzing HM, Hoffland GA et al (2011) Contributors to secondary osteoporosis and metabolic bone diseases in patients presenting with a clinical fracture. J Clin Endocrinol Metab 96(5):1360\u20131367. https:\/\/doi.org\/10.1210\/jc.2010-2135","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1378_CR39","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11657-016-0258-3","volume":"11","author":"F Malgo","year":"2016","unstructured":"Malgo F, Appelman-Dijkstra NM, Termaat MF, van der Heide HJ, Schipper IB, Rabelink TJ, Hamdy NA (2016) High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD. Arch Osteoporos 11(1):12. https:\/\/doi.org\/10.1007\/s11657-016-0258-3","journal-title":"Arch Osteoporos"},{"issue":"7","key":"1378_CR40","doi-asserted-by":"publisher","first-page":"e058983","DOI":"10.1136\/bmjopen-2021-058983","volume":"12","author":"L Vranken","year":"2022","unstructured":"Vranken L, Wyers CE, Van der Velde RY, Janzing HMJ, Kaarsemakers S, Driessen J et al (2022) Association between incident falls and subsequent fractures in patients attending the fracture liaison service after an index fracture: a 3-year prospective observational cohort study. BMJ Open 12(7):e058983. https:\/\/doi.org\/10.1136\/bmjopen-2021-058983","journal-title":"BMJ Open"},{"issue":"18","key":"1378_CR41","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1001\/jama.2010.594","volume":"303","author":"KM Sanders","year":"2010","unstructured":"Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303(18):1815\u20131822. https:\/\/doi.org\/10.1001\/jama.2010.594","journal-title":"JAMA"},{"issue":"2","key":"1378_CR42","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jamainternmed.2015.7148","volume":"176","author":"HA Bischoff-Ferrari","year":"2016","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R et al (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med 176(2):175\u2013183. https:\/\/doi.org\/10.1001\/jamainternmed.2015.7148","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1378_CR43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40520-020-01678-x","volume":"33","author":"R Rizzoli","year":"2021","unstructured":"Rizzoli R (2021) Vitamin D supplementation: upper limit for safety revisited? Aging Clin Exp Res 33(1):19\u201324. https:\/\/doi.org\/10.1007\/s40520-020-01678-x","journal-title":"Aging Clin Exp Res"},{"issue":"4","key":"1378_CR44","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/ajcn\/85.4.1068","volume":"85","author":"Y Song","year":"2007","unstructured":"Song Y, Li TY, van Dam RM, Manson JE, Hu FB (2007) Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 85(4):1068\u20131074. https:\/\/doi.org\/10.1093\/ajcn\/85.4.1068","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"1378_CR45","doi-asserted-by":"publisher","first-page":"701S","DOI":"10.1080\/07315724.2004.10719412","volume":"23","author":"N Saito","year":"2004","unstructured":"Saito N, Tabata N, Saito S, Andou Y, Onaga Y, Iwamitsu A et al (2004) Bone mineral density, serum albumin and serum magnesium. J Am Coll Nutr 23(6):701S-S703. https:\/\/doi.org\/10.1080\/07315724.2004.10719412","journal-title":"J Am Coll Nutr"},{"issue":"4","key":"1378_CR46","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00198-015-3400-y","volume":"27","author":"M Farsinejad-Marj","year":"2016","unstructured":"Farsinejad-Marj M, Saneei P, Esmaillzadeh A (2016) Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int 27(4):1389\u20131399. https:\/\/doi.org\/10.1007\/s00198-015-3400-y","journal-title":"Osteoporos Int"},{"issue":"11","key":"1378_CR47","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1007\/s00198-020-05586-8","volume":"31","author":"A Mott","year":"2020","unstructured":"Mott A, Bradley T, Wright K, Cockayne ES, Shearer MJ, Adamson J et al (2020) Correction to effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int 31(11):2269\u20132270. https:\/\/doi.org\/10.1007\/s00198-020-05586-8","journal-title":"Osteoporos Int"},{"issue":"6","key":"1378_CR48","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/jbmr.3972","volume":"35","author":"P Chotiyarnwong","year":"2020","unstructured":"Chotiyarnwong P, McCloskey E, Eastell R, McClung MR, Gielen E, Gostage J et al (2020) A pooled analysis of fall incidence from placebo-controlled trials of denosumab. J Bone Miner Res 35(6):1014\u20131021. https:\/\/doi.org\/10.1002\/jbmr.3972","journal-title":"J Bone Miner Res"},{"issue":"9","key":"1378_CR49","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/jbmr.4334","volume":"36","author":"M Kistler-Fischbacher","year":"2021","unstructured":"Kistler-Fischbacher M, Yong JS, Weeks BK, Beck BR (2021) A comparison of bone-targeted exercise with and without antiresorptive bone medication to reduce indices of fracture risk in postmenopausal women with low bone mass: the MEDEX-OP randomized controlled trial. J Bone Miner Res 36(9):1680\u20131693. https:\/\/doi.org\/10.1002\/jbmr.4334","journal-title":"J Bone Miner Res"},{"issue":"9391","key":"1378_CR50","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S0140-6736(03)14546-1","volume":"362","author":"R Grol","year":"2003","unstructured":"Grol R, Grimshaw J (2003) From best evidence to best practice: effective implementation of change in patients\u2019 care. Lancet 362(9391):1225\u20131230. https:\/\/doi.org\/10.1016\/S0140-6736(03)14546-1","journal-title":"Lancet"},{"issue":"3","key":"1378_CR51","doi-asserted-by":"publisher","first-page":"101759","DOI":"10.1016\/j.berh.2022.101759","volume":"36","author":"P Geusens","year":"2022","unstructured":"Geusens P, Appelman-Dijkstra NM, Zillikens MC, Willems H, Lems WF, van den Bergh J (2022) How to implement guidelines and models of care. Best Pract Res Clin Rheumatol 36(3):101759. https:\/\/doi.org\/10.1016\/j.berh.2022.101759","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-024-01378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-024-01378-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-024-01378-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T07:05:21Z","timestamp":1734332721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-024-01378-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s11657-024-01378-3","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"10 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JvdB: lecture fees from Amgen, UCB; PG: lecture fees\/advisory boards Sanzoz, MSD, Galapagos, Fresenius, Celltrion, Amgen; NMA-D: lecture fees from Amgen, UCB. Research funding Takeda, Kyowa Kirin, UCB; GdK: lecture fees from Amgen; HW: lecture fees from Amgen, UCB; WFL: lecture fees\/advisory boards from Amgen, UCB, Pfizer, Galapagos; HvdB, PE, MO, MCZ, GdK no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"23"}}